Eli Lilly Pushes Retatrutide Approval to 2027 After Strong Trial Results

The company cited a need for additional time to verify manufacturing and quality-control data, a move intended to meet stringent regulatory standards. Retatrutide distinguishes itself from current market leaders by targeting three distinct hormones—GLP-1, GIP, and glucagon—earning it the nickname "triple G" among industry observers. This mechanism appears to offer superior appetite control compared to existing injections like Zepbound and Wegovy.

Clinical results underscore the drug's potential impact. In one trial, participants with obesity and diabetes achieved an average weight loss of 20.8% over 80 weeks. A second study involving patients with severe obesity and cardiovascular disease saw even higher results, with participants shedding an average of 22.6% of their body weight. These findings add to a growing body of evidence from five late-stage trials, positioning the drug as a future cornerstone of Lilly’s metabolic portfolio. Analysts from TD Cowen project annual sales could reach $3.8 billion by 2030, a vital component of the company’s strategy to maintain its competitive edge in a global weight-loss market expected to reach $100 billion.